Researchers found that knockdown of enhancer of zeste homolog 2 (EZH2) expression restored the expression of deletion gene 1 (DLC1) and inhibited the migration, invasion and proliferation, promoted the apoptosis, and blocked the cell cycle of MDA‐MB‐231 cells.
Shanghai Henlius Biotech, Inc. and Accord Healthcare Limited jointly announced the European Commission has approved Zercepac ® for the treatment of HER2-positive early breast cancer, HER2-positive metastatic breast cancer and HER2-positive metastatic gastric cancer.
The authors document the well‐known miR‐SNPs that are known to be associated with breast cancer. Two principals are discussed: (a) SNPs in the target genes of microRNAs and the alteration in gene expression due to this phenomenon; (b) changes based on the SNPs in the microRNA coding region and the impact on their interaction with target messenger RNA.
Scientists provide an analysis on how ribosomes translate cancer progression with a final focus on the ribosomal receptor for activated C kinase 1 (RACK1) in breast cancer.
The authors reconstituted PTEN-deficient breast cancer cells with wild-type and mutant PTEN, demonstrating that restoration of PTEN expression converted cancer cells with mesenchymal traits to an epithelial phenotype and inhibited cancer stem cell activity.
Researchers evaluated the biological function of a new microenvironment-regulated long non-coding RNA, lncMat2B, in breast cancer. In multicellular tumor spheroids, the expression of lncMat2B presented an increase and a zonal heterogeneity, as it was expressed principally in quiescent cells of hypoxic regions of the multicellular tumor spheroids.
The authors investigated spheroid-forming cells in a metastatic triple-negative breast cancer model. This strategy enabled them to specifically study a population of long-lived tumor cells enriched in cancer stem-like cells, which showed stem-like characteristics and induce metastases.
Scientists summarize the regulatory factors and downstream targets of F-box protein 22 (FBXO22) in cancers, discuss its functions in tumorigenesis, and further highlight the alteration of FBXO22 expression in a variety of human malignancies.
Cheng, J., Lin, M., Chu, M., Gong, L., Bi, Y., & Zhao, Y. (2020). Emerging role of FBXO22 in carcinogenesis. Cell Death Discovery, 6(1), 1–7. https://doi.org/10.1038/s41420-020-00303-0Cite
Scientists summarize the regulatory factors and downstream targets of FBXO22 in cancers, discuss its functions in tumorigenesis, and further highlight the alteration of FBXO22 expression in a variety of human malignancies.
Investigators utilized a 3D co-culture model incorporating estrogen receptor-positive breast cancer cells and bone marrow mesenchymal stem cells to represent disseminated tumors cells in a bone marrow niche.
The SUM Breast Cancer Cell Line Knowledge Base provides information on the derivation of each cell line, provides protocols for the proper maintenance of the cells, and provides a series of data mining tools that allow rapid identification of the oncogene signatures for each line.
Investigators developed an in vitro 3D model comprising a central high-density mass of breast cancer cells surrounded by collagen type-1 and they incorporated fluid flow and pressure.
